2890 related articles for article (PubMed ID: 15223721)
1. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
2. Results of the STOP-Hypertension-2 trial.
Hansson L
Blood Press Suppl; 2000; 2():17-20. PubMed ID: 11055467
[TBL] [Abstract][Full Text] [Related]
3. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
4. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Hansson L
J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
[TBL] [Abstract][Full Text] [Related]
5. [Differential therapy with calcium antagonists].
Scholze JE
Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
8. The case for beta-blockers as first-line antihypertensive therapy.
Cruickshank JM
J Hypertens Suppl; 1992 Jun; 10(3):S21-7. PubMed ID: 1353111
[TBL] [Abstract][Full Text] [Related]
9. [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
Kolloch RE; Rahn KH
Dtsch Med Wochenschr; 1998 Jan; 123(1-2):1-5. PubMed ID: 9465848
[TBL] [Abstract][Full Text] [Related]
10. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
11. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Rahn KH
Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
[TBL] [Abstract][Full Text] [Related]
12. Adult hypertension: reducing cardiovascular morbidity and mortality.
Prescrire Int; 2005 Feb; 14(75):25-33. PubMed ID: 15751180
[TBL] [Abstract][Full Text] [Related]
13. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
14. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
15. First-line therapy for hypertension: different patients, different needs.
Massie BM
Geriatrics; 1994 Apr; 49(4):22-30. PubMed ID: 7909305
[TBL] [Abstract][Full Text] [Related]
16. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
17. [Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension].
Román O; Cuevas G; Bunout D
Rev Med Chil; 1998 Jul; 126(7):745-52. PubMed ID: 9830766
[TBL] [Abstract][Full Text] [Related]
18. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
[TBL] [Abstract][Full Text] [Related]
19. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
Wing LM; Reid CM; Ryan P; Beilin LJ; Brown MA; Jennings GL; Johnston CI; McNeil JJ; Macdonald GJ; Marley JE; Morgan TO; West MJ;
N Engl J Med; 2003 Feb; 348(7):583-92. PubMed ID: 12584366
[TBL] [Abstract][Full Text] [Related]
20. [Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents].
Hildebrandt PR; Tuxen CD; Kjeldsen SE; Lund-Johansen P; Hansson L
Ugeskr Laeger; 2001 Dec; 164(1):18-21. PubMed ID: 11810791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
